Log in to your Inderes Free account to see all free content on this page.
LIDDS
0.11
SEK
0 %
LIDDS
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
0%
-31.25%
-17.91%
-25.17%
+1.85%
-24.4%
-98.91%
-99.24%
-98.85%
liddspharma.com/en/investors
LIDDS is a pharmaceutical company. The company develops pharmaceutical products based on a patent-protected and clinically tested drug delivery technology. The properties of the products form the basis of LIDDS 'technology platform for the development of injectable drug products. LIDDS is the abbreviation for Local Intelligent Drug Delivery System and the company is headquartered in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LIDDS
Daily low / high price
0.11 / 0.11
SEK
Market cap
15.01M SEK
Turnover
1.1K SEK
Volume
10K
Financial calendar
Annual report
20.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Daniel Lifveredson via bolag | 20.5 % | 20.5 % |
Avanza Pension | 7.9 % | 7.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
LIDDS AB (publ) Interim Report January – September 2024
LIDDS has decided to concentrate its activities on three project areas
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio